Welcome to our dedicated page for Cerus SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cerus Corporation filings document financial and governance disclosures for a biomedical products company focused on transfusion safety. Recent 8-K reports furnish operating results, preliminary product revenue, revenue guidance, and business updates tied to the INTERCEPT Blood System, INTERCEPT Fibrinogen Complex, government contract revenue, product margins, and related pipeline activity.
The company’s proxy and material-event filings also cover annual meeting matters, board composition, executive compensation, severance arrangements, compensatory plans, and officer or director changes. These filings provide formal records of Cerus’ public-company governance, Nasdaq-listed common stock reporting, capital-structure disclosures, and material events connected to its blood-safety product business.
Jayaraman Vivek K reported acquisition or exercise transactions in this Form 4 filing.
Cerus Corp Chief Operating Officer Vivek K. Jayaraman reported an award of 420,000 restricted stock units representing common shares on March 2, 2026, at a stated price of $0.00 per share. These RSUs vest in two annual installments, with 34% vesting on March 12, 2027, and 66% vesting on March 12, 2028, contingent on his continuous service with the company through each vesting date.
After this grant, his directly held common stock, including shares from the company’s employee stock purchase plan, totals 1,866,648 shares. This total includes 5,318 shares purchased on August 29, 2025, and 10,004 shares purchased on February 27, 2026, under the employee stock purchase plan.
Jensen Chrystal reported acquisition or exercise transactions in this Form 4 filing.
Cerus Corp reported that Chief Legal Officer Chrystal Jensen received a grant of 300,000 shares of common stock in the form of restricted stock units. These RSUs vest in two steps: 34% on March 12, 2027 and 66% on March 12, 2028, contingent on continued service. After this award, Jensen directly holds 1,028,294 shares.
Cerus Corporation files its annual report describing its INTERCEPT blood safety business and development pipeline. The company sells pathogen-reduction systems for platelets, plasma and cryoprecipitation in the U.S. and multiple international markets, using proprietary compounds and UVA illumination to inactivate viruses, bacteria, parasites and leukocytes.
Cerus is investing heavily in an INTERCEPT red blood cell system, supported by BARDA and DoD contracts, with Phase 3 U.S. trials and a resubmitted MDR application in Europe after an earlier conformity assessment was closed. The filing highlights dependence on key suppliers and government funding, concentrated blood-center customers, extensive global regulation and the risk that the red cell program may never achieve approval or broad adoption, which could prolong operating losses.
Cerus Corporation reported strong 2025 growth with total revenue of $233.8 million, up 16% from 2024. Product revenue rose 14% to $206.1 million, helped by expansion of its INTERCEPT platelet franchise and higher U.S. INTERCEPT Fibrinogen Complex (IFC) sales.
IFC revenue increased about 80% to $16.7 million, and total product gross profit reached $112.3 million with a 54.5% margin, slightly below last year. Net loss narrowed to $15.6 million (or $0.08 per share), while non-GAAP adjusted EBITDA improved to $9.5 million. Cerus ended 2025 with $82.9 million in cash, cash equivalents and short-term investments and generated $4.8 million in operating cash flow for the year. For 2026, the company reaffirms product revenue guidance of $224–$228 million, implying 9%–11% growth, including expected IFC revenue of $20–$22 million, or roughly 20%–30% growth.
Cerus Corporation reported that board member Timothy L. Moore, whose term expires at the 2026 annual meeting of stockholders, has informed the company that he will not stand for re-election at that meeting. The company states that Mr. Moore’s decision is not due to any disagreement with Cerus regarding its operations, policies, or practices. The filing does not indicate any immediate change to the current composition of the board, only that his service will conclude at the end of his present term.
Cerus Corporation reported that it has released preliminary product revenue results for the fourth quarter and full year ended December 31, 2025, along with an outlook, through a press release referenced in this report. These figures are described as preliminary, unaudited and subject to completion of the company’s normal financial closing procedures, and the final results may differ from these early estimates, with any differences potentially being material.
The company notes that its independent registered public accounting firm has not audited or reviewed these preliminary numbers and does not provide any assurance on them. Cerus emphasizes that the product revenue information should not replace full financial statements prepared under U.S. GAAP and cautions against placing undue reliance on the preliminary data. The information in this report and the accompanying press release is being furnished, rather than filed, and is not automatically incorporated into other SEC filings.
Cerus Corporation (CERS) reported an insider stock transaction by its Chief Legal Officer. On 11/24/2025, the officer sold 55,000 shares of Cerus common stock in an open market transaction coded as "S" at a price of $1.70 per share. Following this sale, the officer beneficially owns 728,294 shares of Cerus common stock, held in direct ownership.
Cerus Corporation (CERS) filed its Q3 2025 10‑Q, showing higher sales and near breakeven results. Product revenue reached $52.7 million, up from $46.0 million a year ago, and government contract revenue was $7.5 million versus $4.6 million. Gross profit on product revenue was $28.1 million compared with $26.2 million. The quarter’s net loss attributable to Cerus was $19 thousand, or $0.00 per share.
Operating expenses rose with R&D at $15.8 million and SG&A at $18.6 million. For the nine months, product revenue was $148.4 million and government contract revenue was $20.8 million, with a net loss of $13.4 million. Cash and cash equivalents were $15.7 million and short‑term investments $62.8 million. Total debt was $84.9 million, with $36.2 million classified as current and $48.7 million as non‑current. Inventories increased to $68.1 million, including $53.1 million current. Net cash used in operating activities for the nine months was $1.4 million. As of October 17, 2025, common shares outstanding were 192,087,501. No shares were sold under the at‑the‑market program, leaving approximately $96.8 million available.
Cerus Corporation (CERS) reported its third-quarter 2025 results for the period ended September 30, 2025. The company furnished a press release titled “Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance” as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed filed for liability purposes. An Inline XBRL cover page was included as Exhibit 104.
CERUS CORP reporting person Dean A. Gregory (Director) effected a purchase of 25,000 shares of Cerus common stock on 08/25/2025 at a price of $1.25 per share. After the transaction the reporting person beneficially owned 86,725 shares. The Form 4 was filed by one reporting person and executed by an attorney-in-fact, Chrystal N. Jensen.